Introduction {#Sec1}
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Endoscopic submucosal dissection (ESD) is the preferred treatment method for locally dissecting early gastric cancer (EGC) with a negligible risk of lymph node metastasis \[[@CR1]\]. Currently nearly 100 % curability has been achieved for EGC with radical surgery, thus ESD is also expected to be performed at a comparable success rate. Metachronous recurrence of EGC after ESD is an important problem, but recurrence can be detected with adequate follow-up endogastroduodenoscopy (EGD), and most patients can receive early endoscopic treatment again \[[@CR2]\]. In Japan, the previous consensus has recommended curative ESD that are indicated only for small intramucosal differentiated-type EGC \[[@CR1]\]. Recently, the criteria have been expanded to other pathological types such as the undifferentiated-type under regulated conditions \[[@CR3]--[@CR5]\].

In Japan, gastric cancer is a major cause of cancer death, and *Helicobacter pylori* infection is considered to be a major cause of gastric cancer \[[@CR6]\]. Although epidemiological studies have shown that there are patients who have a significant familial history of gastric cancer, the pathogenesis of familial gastric cancer (FGC) has not been clearly explained. *CDH1* germline mutations are associated with the development of autosomal cancer syndrome, namely hereditary diffuse gastric cancer (HDGC); about 25--30 % of families fulfilling the clinical criteria for HDGC established by the International Gastric Cancer Linkage Consortium (IGCLC) have constitutional alterations of the *CDH1* gene \[[@CR7]\]. The *CDH1* gene maps to chromosome *16q22.1* and consists of 16 exons that encode E-cadherin, which is a major component of adherens junctions. Carrying the abnormal *CDH1* gene confers more than an 80 % lifetime risk of developing gastric cancer.

In 2012, the first conclusive case of a de novo *CDH1* germline mutation (c.1792 C\>T (R598X)) in a woman whose daughter was diagnosed with early-onset diffuse gastric cancer was reported \[[@CR8]\]. On the other hand, *CDH1* germline mutations can also be identified in sporadic early-onset gastric cancer in less than 4 % of patients who are 35 years of age at the time of diagnosis, presenting as de novo mutations \[[@CR9]\]. Although the incidence of gastric cancer is relatively high in Japan, the detection rate of *CDH1* germline mutations in Japanese patients with FGC is low compared to that in European patients \[[@CR10]\].

We report the first case of early-onset diffuse gastric cancer associated with a de novo large genomic deletion of *CDH1* gene, and the pathological feature including gross appearance of the surgical specimen of the stomach was pathognomonic.

Case report {#Sec2}
===========

An asymptomatic 41-year-old man was admitted to our hospital with EGC revealed by cancer screening EGD. There were no abnormalities in the physical examination or laboratory data, and no medical history of malignant tumors. He smoked 20--60 cigarettes a day for 22 years. An enzyme immunoassay to qualitatively detect serum IgG antibodies to *Helicobacter pylori* was negative. A protruding lesion, 5-mm in size, with erosion was observed on the greater curvature of the antrum and no other lesions were observed endoscopically. Biopsy from the erosion indicated signet-ring cell carcinoma (SRCC). ESD was performed on the lesion in accordance with clinical trial (JCOG1009/1010) \[[@CR5]\], resulting in en bloc resection. Precise pathological examination of 3- to 4-mm slices from the entire specimen revealed a lesion, 13 × 13 mm in size, which was a SRCC limited in the mucosal layer (Fig. [1](#Fig1){ref-type="fig"}a, b). Lymphovascular involvement was not observed and horizontal/vertical margins were negative. According to the above-mentioned pathological analysis, the definitive diagnosis was f Stage IA SRCC (L, Gre, 0-IIb, pT1a, cN0, cH0, cP0, cM0) and resection was thought to be curative \[[@CR1]\].Fig. 1**a** Lesion resected with ESD. Resected specimen was 40 × 38 mm. The lesion was step-sectioned at 3- to 4-mm intervals, and then examined pathologically. Although SRCCs at the biopsy site disappeared (as an *arrow* indicates), the entire specimen revealed a lesion 13 × 13 mm in size (as *white lines* indicate). The resection was curative and the horizontal margin was 6.5 mm. **b** The specimen showed localized neoplastic cells with signet-ring features limited to the mucosal layer. Signet-ring cells are easily detected on Haematoxylin and eosin (H&E) sections

Follow-up EGD performed 2 months later revealed no local recurrences at the ESD site, but three new erosions appeared on the gastric angle and antrum (Fig. [2](#Fig2){ref-type="fig"}a, b). Biopsies from these erosions again indicated multiple lesions of SRCC. Apparently they were likely to be intramucosal, but there was a high incidence of metachronous multiple lesions. We considered the possibility of HDGC that we could not control multiple SRCCs by repeated ESD or distal gastrectomy similar to a previous report \[[@CR11]\]. After the explanation about the risk for recurrence or metachronous lesions in any part of the stomach, next month, a total gastrectomy and Roux-en-Y reconstruction with D2 lymph node dissection were carried out as the patient wished. Postoperative pathological examination revealed that 90 and more lesions, each less than 5-mm in size, showing type 0-IIb SRCCs in the mucosal layer, and they were distributed in the whole stomach (Fig. [3](#Fig3){ref-type="fig"}). The lesions may be missed by a cursory look. The reason for the discrepancy between preoperative endoscopic findings and final pathological diagnosis would be the difficulty in locating endoscopically SRCC foci in the superficial lamina propria, just beneath normal-looking surface epithelium or gastric pits. The tumor cells had a low proliferative index and reduced expression of E-cadherin with immunohistochemistry (Fig. [4](#Fig4){ref-type="fig"}c). We suspected the involvement of a genetic abnormality of *CDH1*, although he had no familial history of gastric cancer and did not meet clinical criteria for HDGC defined by the IGCLC \[[@CR7]\].Fig. 2EGD view 2 months after ESD. EGC is visible as the*arrows* indicate. **a** The posterior wall of the lower gastric body, near the gastric angle. **b** The lesser curvature of the gastric angle and the distal antrumFig. 3Surgical specimen. Postoperative pathological examination revealed 90 and more lesions.*White circles* indicate infiltrating SRCCsFig. 4**a**, **b** Germline copy number change in the *CDH1* gene of a patient. Since there were no point mutation of *CDH1*, the DNAs were tested for large genomic deletions in the *CDH1* gene using the SALSA P083-B1 *CDH1* multiplex ligation-dependent probe amplification (MLPA) kit (MRC-Holland, Amsterdam, The Netherlands). The reactions were performed according to the manufacturer's instruction. The results are presented as the ratios to the normal copy numbers (two in this case). Seventeen columns in the *right side* of the graph are control DNAs. Probe ratios below 0.7 and above 1.3 were regarded as indicative of a decrease and increase, respectively, in the gene dosage. As shown in the figure, unambiguous decreases in exon 11 were noticed in the proband and his son. **c** E-cadherin with immunohistochemistry. E-cadherin expression was suppressed in signet-ring cells, while normal glands were uniformly and intensely positive

After informed consent was obtained, DNA was extracted from the peripheral blood of the patient. First, a polymerase chain reaction (PCR)-direct sequencing analysis was performed for all the exons of *CDH1*, but no mutations were identified. Next, a multiplex ligation dependent probe amplification (MLPA) analysis was performed as previously described \[[@CR12]\] (Fig. [4](#Fig4){ref-type="fig"}a). This revealed that the exon 11 of the CDH1 transcript was heterozygously deleted in this case; thus, a heterozygous c.1566-?\_1711+?del germline mutation existed in the proband. For validation, *CDH1* copy numbers in exons 11 were measured using TaqMan copy number assays according to the manufacturer's instructions, and the copy number was 1 (the normal copy number is 2) (Fig. [4](#Fig4){ref-type="fig"}b).

A program of genetic counseling and DNA testing was provided to other members of his family (Fig. [5](#Fig5){ref-type="fig"}). We could not contact his brother. Predictive genetics testing was performed on his parents and his son. Among family members, his 15-year-old son was a carrier of the mutation, and his 71-year-old father and 65-year-old mother were negative for the familial *CDH1* mutation. These results lead to the conclusion that a large genomic deletion of *CDH1* gene identified in this proband and in his son probably occurred de novo in the proband. The proband's 13-year-old daughter has not yet been tested.Fig. 5Pedigree of family with germline *CDH1* alteration. *Squares* indicate males; *circles* indicate females. *Solid symbols* indicate the gastric cancer patient.*Symbols* with a *slash* indicate deceased individuals. An *arrow points* to the proband. The*numbers*below the *symbols* indicate age at the time family members were analyzed

Discussion {#Sec3}
==========

E-cadherin is a calcium-dependent cell membrane protein involved in cell--cell adhesion and confers cell polarity \[[@CR13]\]. *CDH1* mutations are associated with a risk of early-onset diffuse gastric cancer, in addition to increased risk of lobular breast cancer and signet-ring colon cancer \[[@CR7]\]. There was a report of six patients from one large kindred who underwent total gastrectomy for *CDH1* mutation without any evidence of gastric cancer from detailed preoperative imaging studies, including high magnification endoscopy with methylene blue chromoendoscopy and multiple random biopsies. Each patient was found to have multiple sites of invasive diffuse SRCC without lymph node metastases \[[@CR14]\]. The guideline recommends advising *CDH1* mutation positive patients with normal gastric biopsies to undergo prophylactic gastrectomy once the genetic testing results are known and once individuals are older than 20 years. Rare cases of clinically significant diffuse gastric cancer have been reported in affected families before the age of 18, but the overall risk of diffuse gastric cancer before the age of 20 is low \[[@CR15]\]. In the present case, the proband's children should receive surveillance EGD in the future.

To date, over 100 kindreds with *CDH1* germline mutations have been identified, and few cases of a concluded de novo *CDH1* germline mutation have been reported \[[@CR8]\]. However, we think there are many unidentified patients who were not tested or in whom mutations could not be identified with conventional DNA sequencing. Importantly, 4 % of these mutation positive families exhibited large germline deletions of *CDH1* that were not detectable with conventional DNA sequencing \[[@CR16]\]. Analyses of large genomic deletions with MLPA are recommended in cases where simple DNA sequencing is unrevealing \[[@CR16], [@CR17]\]. We propose that screening for germline large rearrangements of *CDH1* should be included in *CDH1* genetic testing for FGC in young patients with diffuse gastric cancer \[[@CR12]\].

The present report is the first description of a de novo large genomic deletion of the *CDH1* gene associated with the production of a truncated CDH1 protein. The c.1566-?\_1711+?del germline mutation observed in this case has not been reported previously either as a somatic or a germline mutation, so we think this is novel and further characterization of its RNA would be interesting. Importantly, it was verified that this mutation passes the gene on to the proband's offspring without change.

The ESD technique has rapidly permeated worldwide for treating EGC, but obviously it is not suitable for multiple occurrences such as in *CDH1* mutation positive patients. As this instructive case shows, unusual morphologic feature may suggest prepared endoscopists should suspect genetic predisposition. In such a case, genetic counseling should also be provided. A prudent follow-up is necessary not only for the proband but also for the proband's family. When a clinician finds the relatively-young patient who has multiple SRCCs, unusual conditions such as *CDH1* germline mutation should be considered, even if patients have no familial histories of gastric cancer.
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